Target |
Mechanism ERβ agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ERβ agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism THR-β agonists |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Eprotirome ( THR-β ) | Obesity More | Discontinued |
KB-2611 ( THR ) | Skin Diseases More | Discontinued |
MK-6913 ( ERβ ) | Vascular Diseases More | Discontinued |
KB-9520 ( ERβ ) | Depressive Disorder More | Pending |
KB-3305 ( GR ) | Diabetes Mellitus, Type 2 More | Pending |